For the year ending 2025-12-31, MDGL had $98,764K increase in cash & cash equivalents over the period. -$190,020K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -288,284 |
| Stock-based compensation expense | 98,130 |
| Depreciation and amortization expense | 1,506 |
| Amortization of debt issuance costs and discount | 1,604 |
| Amortization and interest accretion related to operating leases | 3,210 |
| Loss on extinguishment of debt | -2,779 |
| Trade receivables, net | 80,654 |
| Inventory | 36,978 |
| Prepaid expenses and other current assets | 34,018 |
| Accounts payable | 5,279 |
| Accrued liabilities | 131,902 |
| Accrued interest, net of interest received on maturity of investments | 5,971 |
| Net cash used in operating activities | -189,553 |
| Purchases of marketable securities | 1,047,510 |
| Sales and maturities of marketable securities | 1,083,297 |
| Acquisition of intangible asset | 3,000 |
| Purchases of property and equipment, net of disposals | 467 |
| Net cash provided by (used in) investing activities | 32,320 |
| Proceeds from issuance or sale of equity-Nonrelated Party | 0 |
| Proceeds from issuance or sale of equity-Related Party | 38,055 |
| Proceeds from issuance of debt | 350,000 |
| Payment of debt issuance costs | 10,407 |
| Repayment of debt | 121,664 |
| Net cash provided by financing activities | 255,984 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 13 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 98,764 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)